- Report
- September 2026
- 362 Pages
Global
From €5339EUR$5,850USD£4,575GBP
- Report
- July 2026
- 160 Pages
Global
From €3030EUR$3,320USD£2,597GBP
€3788EUR$4,150USD£3,246GBP
- Report
- March 2026
- 150 Pages
United States
From €4427EUR$4,850USD£3,793GBP
- Report
- September 2026
- 196 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 186 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- September 2026
- 180 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- January 2026
- 185 Pages
Global
From €3236EUR$3,545USD£2,773GBP
€3595EUR$3,939USD£3,081GBP
- Report
- February 2026
- 250 Pages
Global
From €4098EUR$4,490USD£3,512GBP
- Report
- February 2026
- 250 Pages
Global
From €4098EUR$4,490USD£3,512GBP
- Report
- February 2026
- 250 Pages
Global
From €4098EUR$4,490USD£3,512GBP
- Report
- February 2026
- 250 Pages
Global
From €4098EUR$4,490USD£3,512GBP
- Report
- February 2026
- 250 Pages
Global
From €4098EUR$4,490USD£3,512GBP
- Report
- February 2026
- 250 Pages
Global
From €4098EUR$4,490USD£3,512GBP
- Report
- September 2026
- 450 Pages
Global
From €4564EUR$5,000USD£3,911GBP
- Drug Pipelines
- September 2026
- 150 Pages
Global
From €3423EUR$3,750USD£2,933GBP
- Drug Pipelines
- September 2026
- 150 Pages
Global
From €3423EUR$3,750USD£2,933GBP
- Report
- September 2026
- 200 Pages
Global
From €7293EUR$7,990USD£6,249GBP
- Drug Pipelines
- April 2026
- 280 Pages
Global
From €2738EUR$3,000USD£2,346GBP
- Report
- July 2026
- 160 Pages
Global
From €4335EUR$4,750USD£3,715GBP
- Report
- July 2026
- 160 Pages
Global
From €4335EUR$4,750USD£3,715GBP

Sulfonylureas are a class of drugs used to treat type 2 diabetes. They work by stimulating the pancreas to produce more insulin, which helps the body to better process glucose. They are usually taken orally, and are often used in combination with other diabetes medications. Sulfonylureas are generally well-tolerated, but can cause side effects such as hypoglycemia, weight gain, and gastrointestinal upset.
The sulfonylureas market is a subset of the larger diabetes drugs market. It is a competitive market, with a range of products available from different manufacturers. The market is expected to grow in the coming years, driven by increasing prevalence of diabetes and the development of new drugs.
Some of the major companies in the sulfonylureas market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more